Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years

被引：0
|
作者：
William Fusi-Rubiano
Chandoshi Mukherjee
Mark Lane
Marie D. Tsaloumas
Nicholas Glover
Andrej Kidess
Alastair K. Denniston
Helen E. Palmer
Avinash Manna
Rupal Morjaria
机构：
[1] Queen Elizabeth Hospital Birmingham,Ophthalmology Department
[2] University Hospitals Birmingham NHSFT,undefined
[3] Sandwell & West Birmingham NHS Trust,undefined
[4] Academic Unit of Ophthalmology,undefined
[5] Institute of Inflammation & Ageing,undefined
[6] University of Birmingham,undefined
来源：
BMC Ophthalmology | / 18卷
关键词：
Diabetic Macular Oedema; Iluvien; Diabetic Retinopathy; Fluocinolone Acetonide implant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Clinical efficacy and safety of intravitreal fluocinolone acetonide implant for the treatment of chronic diabetic macular oedema: five-year real-world results
    Dobler, Emilie
    Mohammed, Bashar Raouf
    Chavan, Randhir
    Lip, Peck Lin
    Mitra, Arijit
    Mushtaq, Bushra
    EYE, 2023, 37 (11) : 2310 - 2315
  • [42] Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
    Minnella, Angelo Maria
    Picardi, Stefano Maria
    Maceroni, Martina
    Albanesi, Francesca
    De Siena, Elisa
    Placidi, Giorgio
    Caputo, Carmela Grazia
    De Vico, Umberto
    Rizzo, Stanislao
    Falsini, Benedetto
    ADVANCES IN THERAPY, 2021, 38 (06) : 3143 - 3153
  • [43] Retinal Morpho-Functional Changes Following 0.19 mg Fluocinolone Acetonide Intravitreal Implant for Chronic Diabetic Macular Edema
    Angelo Maria Minnella
    Stefano Maria Picardi
    Martina Maceroni
    Francesca Albanesi
    Elisa De Siena
    Giorgio Placidi
    Carmela Grazia Caputo
    Umberto De Vico
    Stanislao Rizzo
    Benedetto Falsini
    Advances in Therapy, 2021, 38 : 3143 - 3153
  • [44] FLUOCINOLONE ACETONIDE 0.2μg/DAY (ILUVIEN®) FOR THE TREATMENT OF CHRONIC DIABETIC MACULAR OEDEMA: AN ITALIAN REAL-WORLD EXPERIENCE
    Capone, L.
    Lattanzio, R.
    Bandello, F.
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2019, 29 (03) : NP17 - NP17
  • [45] Real-world retrospective comparison of 0.19 mg fluocinolone acetonide and 0.7 mg dexamethasone intravitreal implants for the treatment of diabetic macular edema in vitrectomized eyes
    Coelho, Joao
    Malheiro, Luisa
    Beirao, Joao Melo
    Meireles, Angelina
    Pessoa, Bernardete
    CLINICAL OPHTHALMOLOGY, 2019, 13 : 1751 - 1759
  • [46] A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes
    Estebainha, Raquel
    Goldhardt, Raquel
    Falcao, Manuel
    CURRENT OPHTHALMOLOGY REPORTS, 2020, 8 (01) : 1 - 10
  • [47] A New Approach for Diabetic Macular Edema Treatment: Review of Clinical Practice Results with 0.19 mg Fluocinolone Acetonide Intravitreal Implant Including Vitrectomized Eyes
    Raquel Estebainha
    Raquel Goldhardt
    Manuel Falcão
    Current Ophthalmology Reports, 2020, 8 : 1 - 10
  • [48] Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
    Michal Pochopien
    Annette Beiderbeck
    Phil McEwan
    Richard Zur
    Mondher Toumi
    Samuel Aballéa
    BMC Health Services Research, 19
  • [49] Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies
    Pochopien, Michal
    Beiderbeck, Annette
    McEwan, Phil
    Zur, Richard
    Toumi, Mondher
    Aballea, Samuel
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (1)
  • [50] Intravitreal fluocinolone acetonide 0.19 mg (Iluvien®) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients
    Anne Studsgaard
    Kåre Ørts Clemmensen
    Mette Slot Nielsen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260 : 1633 - 1639
12345